

Markey Cancer Center and National Cancer Institute Update



Markey Cancer Affiliate Network Annual Meeting

April 26, 2013



Our Mission

To reduce cancer mortality in our region through a comprehensive program of cancer research, treatment, education, and community engagement with a particular focus on the underserved population of Appalachian Kentucky.



Markey makes a difference.

Significant Burden of Cancer in Kentucky


1st in the nation in overall cancer mortality rate

2nd highest incidence rate for all cancer sites

- Lung and bronchus (1st); colon and rectum (1st); oral cavity and pharynx (1st); kidney and pelvis (2nd); brain (3rd); cervix (8th)
- Cancer incidence and mortality are highest in Appalachia, especially for lung, colorectal, and cervical cancer


Age-adjust	Age-adjusted cancer mortality rates, 2005 – 2009					
	All Cancers	Lung	Colorectal	Cervical		
U.S.	178.7	50.6	16.1	2.4		
Kentucky [†]	211.3	74.0	19.8	2.9		
Appalachian Kentucky*	227.6	84.0	21.3	3.6		
t p<0.05 vs U.S. as a whole: * p<.05 vs Kentucky as a whole. National Cancer for Health Statistics and Kentucky Cancer Registry.						

Appalachian Kentucky



Appalachian county economic status (2011-12)

MCC Catchment Area



NCI Designation


APPLICATION SUBMITTED Sept. 25, 2012

Site visit completed Jan. 30, 2013





Draft comments received March 18, 2013

MCC Research Programs



MCC Shared Resources






Other NIH, 32%

Funding source	Total # of projects	Sum of direct costs	Sum of total costs
NCI	49	\$7,635,845	\$10,103,084
Other NIH	40	\$6,582,993	\$9,163,027
ACS, NSF, Other Peer Reviewed	13	\$3,778,808	\$4,780,801
Non Peer Reviewed	49	\$4,563,097	\$4,821,544
Total	151	\$22,560,743	\$28,868,456

Increased Therapeutic Trial Accruals

(updated: January 1, 2012 to December 31, 2012)



*52% Appalachian residents

Training the Next Generation of Transdisciplinary Cancer Scientists



- "Training Program in Oxidative Stress and Nutrition" (T32 DK007778)[†]
- "Molecular Mechanisms of Toxicity Training Grant" (T32 ES007266)[†]
- "UK Cancer Nanotechnology Training Center" (R25 CA153954)*
- "Oncology Research Training for Surgeon Scientists" (T32 CA160003)*
- "Physician Training Award in Cancer Prevention" (ACS)*
- "Interdisciplinary Research Training in Cancer Biology" (T32 CA165990)*

(†Renewed since 2009; *New since 2009)

Pilot Funds: Return on Investment (2007 – 2012)

50 Pilot Projects awarded – \$4.5M 23 received external grant awards - \$17.3M

Tobacco regulatory science studies

Wnt/β-catenin inhibition by resveratrol and its derivatives

Mc1r in melanocyte UV-induced DNA damage and repair Identification of novel lung cancer proteins




E. Hirschowitz, MD (DT) R01 CA100323 R03 CA162520 Clinical Trial



E. Hahn, RN, PhD (CP) R01 ES021502 P50 (Pending)

C. Liu, PhD (CS) R21 CA139359 Liu-Watt, LLC





Achieving Bench-to-Bedside Translation

- Over the last 5 years, 6 concepts, compounds, or devices developed by MCC investigators have entered clinical development
- Many other projects at various stages of preclinical development

Basic research	Prototype design or discovery	
- Ruthenium complexes	- Hyperthermia in NSCLC	- DMAPT (Phase I)
Prenyl function inhibitors	- Amifostine aerosol	- AR-67 (Phase II)
PAR4 secretagogues Snail function inhibitors	 FIDAS analogs for hMAT2A inhibition 	- Bortezomib in AML (Phase III)
4E-BP1 phosphorylation inhibitors	- Immunoproteasome inhibitor (UK-101)	- NSCLC vaccine (pilot)
pRNA delivery system	- Thiaminase	 MESNA plus doxorubicin (pilot)
	- Mithramycin analog	- XRT optical monitoring (pi

Impactful

Innovative

Collaborative

Dynamic

Transformative












Markey makes a difference.




Impact score: mid-May


Council decision: end of June

MCC Update

Clinical Growth 2012 - 2013

UK HealthCare Growth





FY13 Clinical Recruits



Lars Wagner, MD Professor, Department of Pediatrics Division Chief, Pediatric Oncology

- Recruited from Cincinnati Children's Hospital



Patrick O'Donnell, MD, PhD Assistant Professor, Department of Orthopedics

 Completed fellowship at University of Toronto, Mt. Sinai Hospital



Jerry Martin, MB, BCh Assistant Professor, Department of Surgery Division of Cardiothoracic Surgery

- Completed fellowships at UK and Duke University

Research Growth 2012-2013

FY13 Grants Awarded-selected

PI	Sponsor	Grant Number	Dates	Title	Total
Bondada, Subbarao	NCI	R01 CA165469	2/7/13-1/31/18	Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia	\$297,793
Glazer, Edith	ACS	RSG-13-079-01-CDD	1/1/13-12/31/16	Ruthenium Complex Scaffolds for the Creation of Targeted Chemotherapeutics	\$238,333
Hahn, Ellen	NIEHS	R01 ES021502	9/1/12-5/31/17	FRESH: Dual Home Screening for Lung Cancer Prevention	\$450,790
Hahn, Ellen	KYDPH	PON272812000 022781	7/1/12-6/30/13	Community Partnerships for Tobacco Use Prevention (KDPH)	\$114,263
Kyprianou, Natasha	Sanofi Aventis	NA	11/1/12-10/31/13	Effect of Microtubule-Targeting Chemotherapy on EMT in Prostate Cancer Model	\$120,469
Li, Guo-Min	NCI	R01 CA167181	2/15/13-1/31/18	Novel Mechanism of Genome Instability in Colorectal Cancer	\$231,103
Plattner, Rina	NCI	R01 CA166499	9/12/12-8/31/17	A Role for c-Abl/Arg in Melanoma Progression	\$315,543
Rangnekar, Vivek	NCI	T32 CA165990	4/1/13-3/31/16	Interdisciplinary Research Training in Cancer Biology	\$209,977
She, Qing-Bai	NCI	R01 CA175105	4/1/13-3/31/13	Targeting Translation Dependence in Colorectal Cancer Progression	\$232,854
Shi, Xianglin	NIEHS	R01 ES020137	9/1/12-5/31/13	MicroRNA-190 and Oxidative Stress in Arsenic Carcinogenesis	\$100,238
Spear, Brett	NIGMS	R25 GM102776	9/1/12-6/30/17	Kentucky Bridge to a Biomedical Doctorate for Appalachian Students	\$230,799
Zhang, Joy	NCI	R03 CA171604	9/1/12-8/31/14	Apple Peel Extract Inhibits Cr(VI)-induced Lung Cancer	\$74,250
				Total of All Grants	\$4,861,167

FY13 Research Recruits



Brady Reynolds, Ph.D. Associate Professor, Behavioral Science

- Recruited from The Ohio State University



Meenakshi Upreti, Ph.D. Assistant Professor, Pharmaceutical Science

- Recruited from the University of Arkansas for Medical Sciences

Other Achievements 2012 - 2013

National / International Conferences


2012


reast Translational Group

- Natural Products Symposium, August
- Inaugural Neuro-Oncology Mini Symposium, November

2013

- Inaugural Breast Cancer Symposium, March
- 2nd International Conference of RNA Nanotechnology and Therapeutics, April 3-5
- Neuroendocrine Tumor Regional Conference, April 19-20
- Upcoming:
 - 15th Annual Midwest DNA Repair Symposium, May 18







International Conference of RNA Nanotechnology and Therapeutics



Organized and chaired by Dr. Peixuan Guo 200+ participants from around the world (15 countries)

DanceBlue 2013



Markey Affiliate Network


Markey Cancer Center Affiliate Network

UK Markey Cancer Center Affiliates

- Ashland: Our Lady of Bellefonte Hospital
- Cynthiana: Harrison Memorial Hospital
- Danville: Commonwealth Cancer Center
- Frankfort: Frankfort Regional Medical Center
- Georgetown: Georgetown Community Hospital
- Hazard: Appalachian Regional Healthcare
- Louisville: Norton Cancer Institute
- Morehead: St. Claire Regional Medical Center
- Mt. Vernon: Rockcastle Regional Hospital and Respiratory Care Center

Potential Future Affiliates

• Elizabethtown: Hardin Memorial Hospital



MCCAN New Programs and Services for 2013

- MCCAN Case Conference Series
 - Broadcast live via UK TeleCare and webcast via CECentral
 - Continuing education credit offered
- Assistance with ACoS Commission on Cancer Accreditation
- Telegenetic Counseling Program

Closing Remarks

MCC Strategic Goals

- Goal 1: To establish the MCC as a transformational center dedicated to the prevention of cancers and the reduction of cancer burden and disparities with a focus on rural underrepresented communities of Appalachian Kentucky
- Goal 2: To be a nationally recognized leader in the diagnosis and treatment of cancers that have high incidence rates in Kentucky
- Goal 3: To increase MCC investigator-initiated clinical research and clinical trial accruals

Summary

Over the next 5 years, the MCC needs to ...

- Be bigger and stronger from a clinical and research perspective
- Increase our cancer-related funding
- Increase therapeutic clinical trial accruals to >15% of new patients
- Increase interactions with our affiliate hospitals
- Better consolidate and focus our educational mission
- **Take Markey discoveries to clinical trials**
- Maintain and increase our focus and interactions in our catchment population of Appalachian Kentucky

Thank you!

